Literature DB >> 12753280

Heart valve calcification and calcium x phosphorus product in hemodialysis patients: analysis of optimum values for its prevention.

Margarita Rufino1, Sagrario García, Alejandro Jiménez, Alejandra Alvarez, Rosa Miquel, Patricia Delgado, Domingo Marrero, Armando Torres, Daniel Hernández, Victor Lorenzo.   

Abstract

BACKGROUND: Prevalence of valve calcification (VC) in end-stage renal disease (ESRD) patients is high and information regarding modifiable predictors is scarce. Our aim was to determine the prevalence of VC in our maintenance hemodialysis (HD) population, and the optimal Ca x P value that most accurately predicted the presence of VC after controlling for comorbidities.
METHODS: This was a cross-sectional observational study of a cohort of 52 stable patients on maintenance HD for more than 12 months. Mean 12 months serum biochemical data (calcium, phosphorus, PTH, lipids) and M-mode 2D echocardiogram were used to evaluate the presence or absence of mitral and aortic VC and ventricular geometry.
RESULTS: Twenty patients (38.4%) presented with VC. Patients with VC were more commonly diabetic and showed higher levels of serum phosphorus, Ca x P product, total and LDL cholesterol, and poor ventricular geometry, as compared to patients without VC. Moreover, they required higher doses of both CaCO3 and Al(OH)3. Logistic regression analysis showed that VC was independently influenced by age, Ca x P, and diabetes. ROC curves illustrated that a Ca x P>43 mg2/dL2 was the optimal value in terms of sensitivity and specificity for predicting the presence of VC in our patient population.
CONCLUSION: These findings highlight the importance of applying more vigorous measures for Ca x P control.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12753280     DOI: 10.1046/j.1523-1755.63.s85.27.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  7 in total

1.  Impact of secondary hyperparathyroidism on ventricular mass regression after aortic valve replacement for aortic stenosis in hemodialysis-dependent patients.

Authors:  Yoshiyuki Takami; Kazuyoshi Tajima
Journal:  Heart Vessels       Date:  2014-04-24       Impact factor: 2.037

Review 2.  Cardiac imaging in patients with chronic kidney disease.

Authors:  Diana Y Y Chiu; Darren Green; Nik Abidin; Smeeta Sinha; Philip A Kalra
Journal:  Nat Rev Nephrol       Date:  2015-01-06       Impact factor: 28.314

Review 3.  The Relationship Between Atrial Fibrillation and Chronic Kidney Disease : Epidemiologic and Pathophysiologic Considerations for a Dual Epidemic.

Authors:  David D McManus; Jane S Saczynski; Jeanine A Ward; Khushleen Jaggi; Peter Bourrell; Chad Darling; Robert J Goldberg
Journal:  J Atr Fibrillation       Date:  2012-06-15

Review 4.  Mechanisms of the cardiorenal syndromes.

Authors:  M Khaled Shamseddin; Patrick S Parfrey
Journal:  Nat Rev Nephrol       Date:  2009-09-29       Impact factor: 28.314

Review 5.  Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective.

Authors:  Yogesh Nv Reddy; Varun Sundaram; Georgi Abraham; Prethivee Nagarajan; Yuvaram Nv Reddy
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-10-23

6.  The Association of Calcium-Phosphorus Product With the Severity of Cardiac Valves Failure in Patients Under Chronic Hemodialysis.

Authors:  Simindokht Moshar; Seyedehsara Bayesh; Maryam Mohsenikia; Reza Najibpour
Journal:  Cardiol Res       Date:  2016-05-04

7.  Relationship between Calcium-Phosphorus Product and Severity of Valvular Heart Insufficiency in Patients Undergoing Chronic Hemodialysis.

Authors:  Masoumeh Kahnooj; Mohammad Masoomi; Ali Naderinasab; Akram Zaeem; Mehrdad Sheikhvatan
Journal:  J Tehran Heart Cent       Date:  2010-05-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.